5 ASX 200 shares that inflation can't touch: expert

Regardless of whether you're a bull or a bear, cost pressures are a factor when buying stocks at the moment.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One lesson out of last month's reporting season was that cost pressures are persisting for ASX-listed companies.

That's the analysis from Wilsons equity strategist Rob Crookston, who argued that the biggest pressure for businesses at the moment is labour costs.

"For instance, Cleanaway Waste Management Ltd (ASX: CWY) reported a heightened number of job vacancies caused employee costs to rise +16% due to the need to pay more overtime and use more expensive labour hire contractors," he said in a Wilsons memo to clients.

While in the longer term, inflation will settle down, according to Crookston, its effects can't be ignored when deciding which ASX shares to buy at the moment.

"The near-term threat to profitability is… meaningful and we see further downside to margins from here, particularly in more cyclical sectors with less pricing power — e.g. retail, discretionary goods."

So which are the best ASX shares to buy under such conditions?

Five retirees do a conga line dance on the beach celebrating the special dividend announced by Grange Resources today

Image source: Getty Images

Nothing beats setting your own prices

According to Crookston, "the best defence against cost inflation is pricing power".

"High quality companies with resilient customer demand through the cycle and dominant market positions operating in attractive industry structures are best placed to protect their margins by raising prices."

He named five such S&P/ASX 200 Index (ASX: XJO) stocks that the Wilsons team holds in its focus portfolio:

CSL can set its own prices as the "dominant and lowest-cost player" in the international blood plasma industry, said Crookston.

"The market for immunoglobulin (IG) products is supply constrained, while underlying demand is highly defensive given IG is used to treat patients with a range of serious immunologic and neurologic diseases."

Another medical player, ResMed, already has about 70% of the sleep apnea device market. According to Crookston, it's on its way to supplying the entire market because its nearest rival, Koninklijke Philips NV (AMS: PHIA), is still hamstrung from a 2021 product recall.

Telstra, whose dominance goes without saying for most Australians, is "committed to raising prices annually (and cutting costs) to offset inflation".

"Mobile net ads were strong in 1H23 in spite of higher prices, and the competitive setting is increasingly rational."

In the recession-resilient insurance industry, IAG can name its own prices.

"Number 1 general insurer in Australia, which has been [raising] premium rates strongly to offset rising perils costs (albeit there is a timing lag to margins)," said Crookston.

"Even with higher premiums, customer retention rates remain high."

He noted that The Lottery Corporation operates in a monopoly in every state except for Western Australia.

"Lottery sales have historically been [highly] resilient in economic downturns, and TLC has a proven ability to incrementally raise ticket prices over time."

Motley Fool contributor Tony Yoo has positions in CSL and ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed and Telstra Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Man sitting in a plane seat works on his laptop.
Broker Notes

Down 34% in 2026, are Virgin Australia shares a good buy today?

A leading analyst delivers his outlook for Virgin Australia’s beaten-down shares.

Read more »

Red buy button on an Apple keyboard with a finger on it.
Broker Notes

Brokers name 3 ASX shares to buy right now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A smiling woman holds a Facebook like sign above her head.
Broker Notes

Why these ASX shares are rated as buys in April

Let's see what makes them bullish on these names right now.

Read more »

Australian dollar notes in the pocket of a man's jeans, symbolising dividends.
Broker Notes

Are CBA shares still a good buy for passive income?

A leading analyst delivers his verdict on CBA’s passive income appeal.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Broker Notes

Morgans names 2 ASX shares to buy and 1 to accumulate

What is the broker recommending investors do with these shares?

Read more »

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

2 ASX 200 shares to buy ahead of anticipated rally: expert

After a 9.1% drop between 27 February and 23 March, the ASX 200 reversed course last Tuesday.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Broker Notes

Bell Potter says this ASX 200 stock can rise 38% and pay a 6% dividend yield

Major upside and a generous dividend yield could be on offer with this name.

Read more »